← Leaderboards
Petros C Karakousis
Johns Hopkins University
$19,415,784
Attributed
$26,965,414
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,067,797 · 17
By mechanism
R01$17,144,426 · 6
P30$4,958,214 · 3
UH3$4,330,997 · 1
R21$1,807,200 · 4
UH2$1,191,495 · 1
K24$955,975 · 1
Top collaborators
- Richard B. Markham7 shared
- Richard E Chaisson5 shared
- Maria Laura Gennaro5 shared
- Joel S. Bader4 shared
- Anne Hamacher-Brady1 shared
- Sanjay Jain1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Lori Latowski Grover$726,284
- Roger H Reeves$24,667,280
- Richard E Chaisson$50,014,616
- Nicholas J Maragakis$2,959,620
- Marcus Barreto Conde$983,132
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisTuberculosisTuberculosis TreatmentAnimal ModelPharmaceutical PreparationsLungInfectionPathway InteractionsResponseRegimenAntibioticsGrowthCollaborationsImmuneIn VitroCytokineResearch PersonnelMicrobiologyLesionGenesPulmonary TuberculosisAntitubercular AgentsMouse ModelMediating
Grant awards (56)
Advancing Apoptosis-Inducing Agents as Host-Directed Therapy for TB$2,922,220
R01 · FY2025 · AI · contact PI
JHU TRAC: Training and Supporting the Next Generation of TB Researchers$980,674
P30 · FY2025 · AI · contact PI
Administrative Core$317,337
P30 · FY2025 · AI · contact PI
JHU TRAC: Training and Supporting the Next Generation of TB Researchers$980,674
P30 · FY2024 · AI · contact PI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$778,923
R01 · FY2024 · AI · contact PI
Characterizing CaeA-mediated rifampin tolerance in MTB$212,621
R21 · FY2024 · AI · contact PI
Administrative Core$193,973
P30 · FY2024 · AI · contact PI
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV$191,195
K24 · FY2024 · AI · contact PI
Ethics of Including Pregnant People in Clinical Trials$163,750
P30 · FY2024 · AI · contact PI
JHU TRAC: Training and Supporting the Next Generation of TB Researchers$980,674
P30 · FY2023 · AI · contact PI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$740,856
R01 · FY2023 · AI · contact PI
Characterizing CaeA-mediated rifampin tolerance in MTB$253,328
R21 · FY2023 · AI · contact PI
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV$191,195
K24 · FY2023 · AI · contact PI
Administrative Core$189,807
P30 · FY2023 · AI · contact PI
JHU TRAC: Training and Supporting the Next Generation of TB Researchers$996,611
P30 · FY2022 · AI · contact PI
Foam cells as drug targets in tuberculosis$787,112
R01 · FY2022 · HL
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$749,043
R01 · FY2022 · AI · contact PI
Administrative Core$154,714
P30 · FY2022 · AI · contact PI
Foam cells as drug targets in tuberculosis$787,897
R01 · FY2021 · HL
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$758,696
R01 · FY2021 · AI · contact PI
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV$191,195
K24 · FY2021 · AI · contact PI
Foam cells as drug targets in tuberculosis$787,457
R01 · FY2020 · HL
Effects of donor plasma and recipient characteristics on convalescent plasma treatment outcome of COVID-19$753,853
R01 · FY2020 · HL
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$732,434
R01 · FY2020 · AI · contact PI
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV$191,195
K24 · FY2020 · AI · contact PI
Statins as Adjunctive, Host-Directed Therapy for TB$1,463,317
UH3 · FY2019 · AI · contact PI
Foam cells as drug targets in tuberculosis$801,457
R01 · FY2019 · HL
Immunotherapy Targeting MTB Persisters in the DC-impaired Setting of HIV and TB$204,688
R21 · FY2019 · AI · contact PI
Mentoring in Immunometabolic Dysregulation in TB and TB/HIV$191,195
K24 · FY2019 · AI · contact PI
Statins as Adjunctive, Host-Directed Therapy for TB$1,463,190
UH3 · FY2018 · AI · contact PI
Immunotherapy Targeting MTB Persisters in the DC-impaired Setting of HIV and TB$245,563
R21 · FY2018 · AI · contact PI
Statins as Adjunctive, Host-Directed Therapy for TB$1,404,490
UH3 · FY2017 · AI · contact PI
A novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient host$202,500
R21 · FY2017 · AI · contact PI
Statins as Adjunctive, Host-Directed Therapy for TB$591,785
UH2 · FY2016 · AI · contact PI
A novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient host$243,000
R21 · FY2016 · AI · contact PI
Validation of RelA as a Target for Mycobacterium Tuberculosis Persisters$243,000
R21 · FY2016 · AI · contact PI
Statins as Adjunctive, Host-Directed Therapy for TB$599,710
UH2 · FY2015 · AI · contact PI
The Role of Cell Wall Lipids in Pathogenesis of Rifampin-Resistant TB$282,430
R01 · FY2015 · AI · contact PI
Validation of RelA as a Target for Mycobacterium Tuberculosis Persisters$202,500
R21 · FY2015 · AI · contact PI
The Role of Cell Wall Lipids in Pathogenesis of Rifampin-Resistant TB$197,159
R01 · FY2014 · AI · contact PI
The Role of Cell Wall Lipids in Pathogenesis of Rifampin-Resistant TB$85,739
R01 · FY2014 · AI · contact PI
A Multidisciplinary Approach to Understanding TB Latency and Reactivation$716,068
R01 · FY2013 · HL · contact PI
Regulatory networks involved in Mycobacterium tuberculosis persistence$549,051
R01 · FY2013 · AI · contact PI
The Role of Cell Wall Lipids in Pathogenesis of Rifampin-Resistant TB$199,999
R01 · FY2013 · AI · contact PI
A Multidisciplinary Approach to Understanding TB Latency and Reactivation$769,928
R01 · FY2012 · HL · contact PI
Regulatory networks involved in Mycobacterium tuberculosis persistence$527,030
R01 · FY2012 · AI · contact PI
A Multidisciplinary Approach to Understanding TB Latency and Reactivation$788,317
R01 · FY2011 · HL · contact PI
Regulatory networks involved in Mycobacterium tuberculosis persistence$574,242
R01 · FY2011 · AI · contact PI
A Multidisciplinary Approach to Understanding TB Latency and Reactivation$800,674
R01 · FY2010 · HL · contact PI
Regulatory networks involved in Mycobacterium tuberculosis persistence$514,756
R01 · FY2010 · AI · contact PI
Regulatory networks involved in Mycobacterium tuberculosis persistence$539,085
R01 · FY2009 · AI · contact PI
Modeling latent TB Infection$142,851
K08 · FY2009 · AI · contact PI
Modeling latent TB Infection$139,320
K08 · FY2008 · AI · contact PI
Modeling latent TB Infection$135,891
K08 · FY2007 · AI · contact PI
Modeling latent TB Infection$132,464
K08 · FY2006 · AI · contact PI
Modeling latent TB Infection$128,964
K08 · FY2005 · AI